Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $110.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 315.03% from the company’s previous close.

Several other research firms have also weighed in on MAZE. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday. Finally, Citigroup assumed coverage on Maze Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $63.40.

Maze Therapeutics Trading Down 5.6%

Maze Therapeutics stock traded down $1.59 during mid-day trading on Thursday, hitting $26.50. The stock had a trading volume of 160,297 shares, compared to its average volume of 658,983. The stock has a 50-day simple moving average of $27.18 and a two-hundred day simple moving average of $29.17. The stock has a market capitalization of $1.47 billion, a PE ratio of -10.48 and a beta of 2.17. Maze Therapeutics has a 12 month low of $21.95 and a 12 month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). As a group, sell-side analysts forecast that Maze Therapeutics will post -2.72 EPS for the current year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at $445,680.62. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at $717,675. This trade represents a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,459 shares of company stock valued at $5,263,539 in the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $48,000. Royal Bank of Canada boosted its holdings in Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares in the last quarter. Quantbot Technologies LP bought a new position in Maze Therapeutics in the second quarter worth approximately $80,000. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics in the fourth quarter worth approximately $145,000. Finally, IFP Advisors Inc purchased a new stake in shares of Maze Therapeutics in the fourth quarter worth approximately $146,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.